Nephros Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nephros Inc (NEPH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Nephros Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 22M vs 86,257M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+11.0% annualized vs trailing 12 months), vs holding steady (+0.3%) for its tracked peer group.
- Growth: Nephros Inc generated 58.6% revenue growth year over year in Q2 2026, vs 5.3% for its competitors combined.
- Profitability: Its 19.9% net margin compares with 16.4% for the peer group.
- Scale: Nephros Inc ranks #150 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Nephros Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.60M compares with $0.33M for the peer group (1.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NEPH Sales vs. its Competitors, Q2 2026
Nephros Inc reported revenue growth of 58.55 % year on year in Q2 2026, above its competitors' combined revenue growth of 5.26 %.
With a net margin of 19.89 %, Nephros Inc achieved higher profitability than its competitors (16.43 %).
Nephros Inc generated 0.03 % of the combined sales of its peer group, up from 0.02 % a year earlier.
Nephros Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Nephros Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Nephros Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Nephros Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Nephros Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.8% year over year, combined, vs 58.6% for Nephros Inc. Nephros Inc's share of combined industry revenue moved from 0.00% to 0.01%, a gain of 0.00 percentage points.
Nephros Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nephros Inc | Yes | Yes | Yes | No |
| Competitors combined (10) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NEPH Stock Performance relative to its Competitors
NEPH Stock Performance relative to High-Confidence Competitors
NEPH Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Rockwell Medical inc | 282.9% | Outperformed |
| 2 | Davita Inc | 282.9% | Outperformed |
| 3 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Danaher Corporation | 282.9% | Outperformed |
| 5 | 3m Company | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nephros Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Nephros Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Nephros Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Nephros Inc |
35.23 | 21.69 |
 Danaher Corporation |
164,140.16 | 25,608.00 |
 Regeneron Pharmaceuticals Inc |
97,985.18 | 16,896.20 |
 3m Company |
91,110.08 | 25,247.00 |
 Fresenius Medical Care Ag |
13,086.11 | 22,191.39 |
 Davita Inc |
12,282.00 | 14,167.55 |
| SUBTOTAL | 389,838.44 | 108,470.41 |
Sign in to see all competitors of Nephros Inc .
Sources: Nephros Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nephros Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nephros Inc's Competitors Named by the Company
Competitive relationships identified from Nephros Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Pentair | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| Aquamedix | Company report | 85% |
| Cytiva | Company report | 85% |
| Pall Corporation | Company report | 85% |
| Aquatools | Company report | 85% |
| Baxter International, Inc. | Company report | 85% |
| Nipro Medical Corporation Ltd. | Company report | 85% |
| Toray Medical Co., Ltd. | Company report | 85% |
| Asahi Kasei Medical Co. Ltd. | Company report | 85% |
| Fresenius Medical Care AG | Company report | 85% |
| Spartan Bioscience | Company report | 85% |
| B. Braun Melsungen AG | Company report | 85% |
| Nikkiso Co., Ltd. | Company report | 85% |
| Terumo Medical Corporation | Company report | 85% |
| 3m Company | Company report | 85% |
| Rockwell Medical inc | Company report | 85% |
| Davita Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Nephros Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Nephros Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Nephros Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Danaher Corporation | Diagnostics 43.97 % |
| 3m Company | Safety and Industrial 48.33 % |
| Davita Inc | U. S. Dialysis And Related Lab Services 84.64 % |
| Pentair Plc | Water Solutions 43.21 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Nephros Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nephros Inc | 35 | 602,389 | 48,222 |
| Danaher Corporation | 164,140 | 426,800 | 72,183 |
| Regeneron Pharmaceuticals Inc | 97,985 | 1,096,444 | 312,615 |
| 3m Company | 91,110 | 417,306 | 58,579 |
| Fresenius Medical Care Ag | 13,086 | 202,295 | 12,278 |
| Davita Inc | 12,282 | 181,635 | 15,028 |
| PEERS TOTAL | 389,803 | 325,435 | 47,276 |
Nephros Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Danaher Corporation | North America 41.81 % |
| 3m Company | United States 46.28 % |
| Pentair Plc | United States 69.33 % |
| Rockwell Medical inc | United States 86.19 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Nephros Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Nephros Inc's industry classification, broader than the peer set above. Market cap in millions of $.Nephros Inc ranks #150 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 600, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 154,357 | 13.55 % |
| 2 | Medtronic Plc | 124,064 | 10.89 % |
| 3 | Stryker Corp | 112,658 | 9.89 % |
| 4 | 3m Company | 91,075 | 8.00 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Dexcom Inc | 1,234 | 5.2% |
| 150 | Nephros Inc | 35 | 0.00 % |
Market cap and industry share for the rest of Nephros Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-30.
Nephros Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 145 | Sanuwave Health Inc | 44 | -83.71 % |
| 146 | Precision Optics Corporation Inc | 40 | 7.51 % |
| 147 | Inspiremd Inc | 38 | -80.20 % |
| 148 | Cvrx inc | 37 | -86.73 % |
| 149 | Star Equity Holdings Inc | 1,234 | 12.3% |
| 150 | Nephros Inc | 35 | -31.91 % |
| 151 | Nexalin Technology Inc | 1,234 | 12.3% |
| 152 | Nyxoah Sa | 1,234 | 12.3% |
| 153 | Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter ___ | 1,234 | 12.3% |
| 154 | Nexgel Inc | 1,234 | 12.3% |
| 155 | Heartbeam Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Nephros Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Nephros Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (320 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.61 % | 22.21 % (avg) | -21.6 pp |
| Operating Margin | 0.08 % | industry median | +0.1 pp |
| EBITDA Margin | 1.63 % | -4.56 % (avg) | +6.2 pp |
| Capital Intensity (Capex / Revenue) | - | 6.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Nephros Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (320 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 20.9x | 36.5x | -15.6x |
| EV / EBITDA | 0.8x | 17.9x | -17.1x |
| P/B | 3.4x | 4.6x | -1.2x |
| Return on Equity | 0.16 % | industry aggregate | -11.82 % |
| Return on Invested Capital | - | -4.40 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Nephros Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 64.18 % | 49.30 % | 81.71 % | 10.82 % | 3.51 % | 33.92 % | 2.37 % | 35.72 % |
| Operating Margin | -58.44 % | -53.03 % | -30.53 % | -41.67 % | -41.68 % | -11.88 % | 0.04 % | 6.15 % |
| Return on Invested Capital | -66.88 % | -27.12 % | -17.47 % | -12.71 % | -15.88 % | -8.84 % | 0.03 % | 5.63 % |
| P/E | - | - | - | - | - | - | 795.6x | 48.6x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Nephros Inc's BCG Growth-Share Matrix
Relative market share (vs Nephros Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Nephros Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.6% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Nephros Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 600 (see Industry Market Structure & Concentration above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Nephros Inc's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Nephros Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Nephros Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Nephros Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+11.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 11.8 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Nephros Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nephros Inc | 1.74 | 4.23 | - |
| Danaher Corporation | - | 1.75 | 0.45 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| 3m Company | - | 1.47 | 3.62 |
| Fresenius Medical Care Ag | 0.26 | 1.26 | 0.51 |
| Davita Inc | 0.21 | 1.39 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nephros Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nephros Inc | Q2 2026 | +58.6 % | +405.1 % |
| Danaher Corporation | Q3 2026 | +8.3 % | +36.0 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| 3m Company | Q3 2026 | +1.0 % | +63.3 % |
| Fresenius Medical Care Ag | Q4 2025 | +6.1 % | +68.0 % |
| Davita Inc | Q3 2026 | +4.6 % | -7.2 % |
| PEERS TOTAL | +7.9 % | +42.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nephros Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nephros Inc | Q2 2026 | +99.1 % | - |
| Danaher Corporation | Q3 2026 | +7.4 % | -12.7 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| 3m Company | Q3 2026 | +0.2 % | +17.4 % |
| Fresenius Medical Care Ag | Q4 2025 | +4.6 % | - |
| Davita Inc | Q3 2026 | - | -4.0 % |
Nephros Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nephros Inc | 12.30% | 15.31% | 16.20% |
| Danaher Corporation | 4.91% | 5.57% | 8.18% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.13% | 15.07% |
| 3m Company | 9.60% | 13.24% | 93.07% |
| Fresenius Medical Care Ag | 3.70% | 4.40% | 8.04% |
| Davita Inc | 6.65% | 6.13% | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nephros Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nephros Inc | 20.42 | 1.62 |
| Danaher Corporation | 38.07 | 6.41 |
| Regeneron Pharmaceuticals Inc | 20.52 | 5.80 |
| 3m Company | 25.98 | 3.61 |
| Fresenius Medical Care Ag | 11.83 | 0.59 |
| Davita Inc | 15.50 | 0.87 |
| PEERS AVERAGE | 24.74 | 3.59 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.